Thailand Cannabis Ban: Medical-Only Law, Policy Reversal & Industry Impact

Executive Summary

Thailand has reimposed strict medical-only cannabis regulations in 2026, reversing its brief experiment as Southeast Asia's first nation to decriminalize recreational marijuana use. The policy shift follows a tumultuous four-year period that began with Thailand's June 2022 delisting of cannabis from its narcotics schedule, which inadvertently created a legal gray zone for recreational sales. The new medical-only framework, enacted through emergency decree in early 2026, requires all cannabis businesses to obtain medical licenses, restricts THC content in consumer products to 0.2 percent, and mandates prescription-only access for higher-potency preparations. Bangkok's once-thriving network of over 6,000 cannabis dispensaries now faces closure or conversion to licensed medical facilities, while thousands of small operators confront financial ruin. The reversal represents a significant setback for cannabis reform advocates across Asia and demonstrates the fragility of liberalization policies in jurisdictions without comprehensive regulatory frameworks.

Why This Matters

Thailand's cannabis policy reversal affects millions of stakeholders across Southeast Asia and sets a cautionary precedent for emerging cannabis markets worldwide. The nation's brief decriminalization period generated an estimated $1.2 billion in cannabis-related economic activity between 2022 and 2025, according to the University of Thai Chamber of Commerce. More than 12,000 registered cannabis businesses employed approximately 45,000 workers directly, with tens of thousands more in ancillary industries including tourism, hospitality, and agriculture.

The medical-only restrictions directly impact Thailand's 70 million citizens, particularly the estimated 800,000 patients who accessed cannabis products for pain management, anxiety, and sleep disorders during the liberalization period. International medical cannabis companies including Canopy Growth Corporation and Aurora Cannabis had invested over $200 million in Thai cultivation facilities and research partnerships, viewing Thailand as a gateway to Asian markets worth a projected $8.5 billion by 2030.

For regional cannabis reform movements, Thailand's reversal provides ammunition to conservative governments in Malaysia, Singapore, and Indonesia that maintain capital punishment for drug trafficking. The policy shift also complicates Thailand's tourism sector, which had marketed cannabis-friendly experiences to attract younger international visitors. Tourism Authority of Thailand data showed cannabis tourism generated approximately $400 million in revenue during 2024 alone.

Background and History

Pre-2018: Traditional Use and Prohibition Era

Cannabis has been cultivated and used medicinally in Thailand for centuries, but modern prohibition began in 1934 under the Narcotics Act. Traditional Thai medicine incorporated cannabis leaves and flowers for pain relief, appetite stimulation, and digestive ailments. Rural communities in northern provinces including Chiang Mai and Chiang Rai maintained small-scale cultivation for personal medicinal use despite legal prohibitions.

Thailand's 1979 Narcotics Act, enacted during the height of the U.S.-led War on Drugs, classified cannabis as a Category 5 narcotic alongside heroin and methamphetamine. Possession carried penalties of up to five years imprisonment and fines reaching 100,000 baht ($2,800). Cultivation and distribution offenses carried sentences up to 15 years. Between 1979 and 2018, Thai authorities arrested an average of 40,000 individuals annually for cannabis-related offenses, according to Office of the Narcotics Control Board statistics.

2018-2019: Medical Cannabis Legalization

Thailand became the first Southeast Asian nation to legalize medical cannabis on December 25, 2018, when the National Legislative Assembly amended the Narcotics Act to reclassify cannabis for medical and research purposes. The amendment, championed by Public Health Minister Piyasakol Sakolsatayadorn, established a framework for licensed cultivation, processing, and distribution of medical cannabis products.

The 2018 reform limited legal access to government hospitals and licensed traditional medicine practitioners. The Government Pharmaceutical Organization began cultivating cannabis at secure facilities in northeastern Thailand, producing standardized extracts with controlled THC and CBD ratios. By December 2019, six government hospitals dispensed cannabis-based medications to approximately 4,800 registered patients, primarily for chemotherapy-related nausea, epilepsy, and chronic pain.

2020-2021: Expansion and Home Cultivation

The Thai government expanded medical cannabis access in January 2020 by permitting licensed private clinics to prescribe cannabis products and allowing limited home cultivation. The Food and Drug Administration issued regulations permitting households to register up to six cannabis plants for personal medicinal use, requiring notification to local authorities. By June 2021, over 180,000 households had registered home cultivation, concentrated in Bangkok and northern provinces.

The Department of Thai Traditional and Alternative Medicine licensed 1,200 traditional medicine clinics to prescribe cannabis preparations by December 2021. However, the medical framework faced criticism for restrictive access requirements, high prescription costs averaging 3,000 baht ($85) per consultation, and limited product availability. Black market cannabis remained widely available at lower prices, undermining the legal medical system.

June 2022: Decriminalization and the Regulatory Vacuum

On June 9, 2022, Thailand's Ministry of Public Health removed cannabis and hemp from the Category 5 narcotics list, effectively decriminalizing possession and cultivation nationwide. The delisting occurred under Public Health Minister Anutin Charnvirakul, leader of the Bhumjaithai Party, who had campaigned on cannabis reform as an economic development strategy for rural agricultural communities.

The delisting created an immediate legal gray zone. While cannabis was no longer a controlled substance, the government had not enacted comprehensive regulations governing commercial sales, product standards, or age restrictions. The Ministry of Public Health issued guidelines prohibiting recreational use and restricting THC content in consumer products to 0.2 percent, but these guidelines lacked enforcement mechanisms and criminal penalties.

Within three months, over 3,000 cannabis dispensaries opened in Bangkok alone, selling high-THC flower, pre-rolled joints, edibles, and concentrates without age verification or potency testing. The rapid commercialization occurred despite the absence of enabling legislation from Thailand's parliament. Provincial governors lacked clear authority to regulate or shut down dispensaries, creating inconsistent enforcement across the country's 76 provinces.

2022-2024: The Cannabis Boom

Thailand's cannabis industry expanded rapidly between June 2022 and December 2024, with registered businesses growing from zero to over 12,000 nationwide. The Department of Thai Traditional and Alternative Medicine, tasked with business registration, approved licenses for cultivation, processing, distribution, and retail sales. Bangkok's tourist districts including Khao San Road, Sukhumvit, and Silom transformed into cannabis retail corridors, with dispensaries occupying prime street-level retail space.

Cannabis cafes and consumption lounges proliferated, offering customers spaces to purchase and consume products on-site. High-end establishments in Bangkok's central business district charged premium prices for imported genetics including California strains like Wedding Cake and Gelato. Budget dispensaries in residential neighborhoods sold locally-grown flower for as little as 200 baht ($5.50) per gram.

The tourism sector embraced cannabis marketing. Hotels offered cannabis-friendly accommodations, tour operators developed cannabis farm visits, and cooking schools added cannabis-infused cuisine classes. The Tourism Authority of Thailand estimated that cannabis-related tourism generated 14 billion baht ($400 million) in revenue during 2024, with international visitors from Europe, North America, and Australia comprising the primary consumer base.

However, the unregulated market created significant public health and safety concerns. Product testing remained voluntary, with no government laboratory capacity to verify THC content or screen for pesticides and heavy metals. Emergency room visits for cannabis-related adverse reactions increased 340 percent between June 2022 and December 2023, according to Ministry of Public Health data. Reports of accidental pediatric ingestion of cannabis edibles rose sharply, with 127 cases documented in 2023 compared to three cases in 2021.

2025: Political Backlash and Reform Efforts

Conservative political parties and medical associations launched campaigns to reverse cannabis decriminalization throughout 2025, citing public health risks and social disorder. The Medical Council of Thailand, representing over 40,000 licensed physicians, issued a statement in March 2025 calling for reimposition of strict medical-only regulations. The Thai Medical Association documented increased cannabis use disorder diagnoses, particularly among adolescents and young adults.

The Move Forward Party, which won the most parliamentary seats in the May 2023 general election, initially supported comprehensive cannabis legalization with age restrictions and taxation. However, the party faced pressure from coalition partners and conservative constituencies concerned about youth access and impaired driving incidents. Parliamentary debates throughout 2025 revealed deep divisions over cannabis policy, with no consensus on regulatory frameworks.

Provincial governors in conservative regions including Nakhon Ratchasima and Ubon Ratchathani issued local orders restricting cannabis sales near schools and religious sites. The Royal Thai Police documented 2,400 arrests for driving under the influence of cannabis in 2025, compared to 180 arrests in 2021. Public opinion polls showed declining support for open cannabis access, with a December 2025 survey by Suan Dusit University finding that 58 percent of respondents favored medical-only regulations.

January-March 2026: Emergency Decree and Implementation

On January 15, 2026, Prime Minister Srettha Thavisin invoked emergency decree powers to reclassify cannabis as a controlled substance requiring medical authorization. The decree, issued under Section 44 of the interim constitution, bypassed parliamentary debate and took immediate effect. The emergency measure cited public health emergencies and the need to comply with international drug control treaties including the 1961 Single Convention on Narcotic Drugs.

The decree established a 90-day transition period ending April 15, 2026, during which existing cannabis businesses could apply for medical licenses or cease operations. The Food and Drug Administration issued implementing regulations requiring medical dispensaries to employ licensed pharmacists, maintain prescription records, and limit THC content to 0.2 percent in over-the-counter products. Products exceeding 0.2 percent THC required physician prescriptions and could only be dispensed at licensed medical facilities.

The transition period created chaos in the cannabis industry. Approximately 85 percent of existing dispensaries lacked the capital, facilities, or qualified personnel to meet medical licensing requirements. Small operators who had invested life savings in inventory, equipment, and leasehold improvements faced total losses. Industry associations including the Thai Cannabis Trade Association filed legal challenges arguing the emergency decree violated constitutional property rights and due process protections.

Key Players

Bhumjaithai Party and Anutin Charnvirakul

The Bhumjaithai Party, led by Deputy Prime Minister and Interior Minister Anutin Charnvirakul, championed cannabis decriminalization as a signature policy initiative. Anutin, who served as Public Health Minister from 2019 to 2023, positioned cannabis reform as an economic development strategy for Thailand's agricultural sector. The party's political base in northeastern provinces stood to benefit from legal cannabis cultivation as an alternative to rice and cassava farming.

Following the 2026 ban, Anutin criticized the emergency decree as politically motivated and economically destructive. The party has pledged to pursue legislative reversal if it gains sufficient parliamentary support, though coalition dynamics make such efforts unlikely before the next general election scheduled for 2027.

Ministry of Public Health and Food and Drug Administration

The Ministry of Public Health and its subordinate Food and Drug Administration hold primary regulatory authority over cannabis under the medical-only framework. Permanent Secretary for Public Health Opas Karnkawinpong oversees implementation of the 2026 restrictions, including medical licensing requirements and product standards. The FDA's Bureau of Drug Control manages the registration system for medical cannabis products and inspects licensed facilities for compliance.

The Ministry faces significant capacity constraints in implementing the new regulatory regime. As of August 2026, the FDA had approved only 340 medical cannabis licenses nationwide, far short of the estimated 2,000 applications submitted during the transition period. Processing delays stem from inadequate staffing and the need to develop entirely new inspection protocols and quality control systems.

Royal Thai Police and Office of the Narcotics Control Board

The Royal Thai Police resumed enforcement of cannabis prohibitions following the April 15, 2026 deadline for compliance with medical-only regulations. The Office of the Narcotics Control Board, under the Ministry of Justice, coordinates enforcement efforts and maintains Thailand's obligations under international drug control treaties. Between April 15 and August 1, 2026, police conducted raids on approximately 1,800 unlicensed cannabis businesses, seizing inventory and arresting operators for unauthorized distribution of controlled substances.

Enforcement has been inconsistent across provinces, with Bangkok Metropolitan Police prioritizing high-profile tourist district operations while rural areas receive limited attention. The ONCB reported seizing over 4,200 kilograms of cannabis flower and 18,000 cannabis-infused products during the first four months of enforcement.

Thai Cannabis Trade Association

The Thai Cannabis Trade Association, representing over 3,000 cannabis businesses, has led industry opposition to the medical-only restrictions. Association president Chokwan Chopaka has organized protests, filed legal challenges, and lobbied parliamentarians for legislative relief. The association estimates that 90 percent of its member businesses will permanently close due to inability to meet medical licensing requirements.

The association has proposed alternative regulatory frameworks including age-restricted adult-use sales with taxation, similar to alcohol regulations. However, these proposals have gained limited traction with conservative coalition partners in the governing coalition.

International Cannabis Companies

Canadian licensed producers Canopy Growth Corporation and Aurora Cannabis invested heavily in Thai cultivation facilities and research partnerships during the liberalization period. Canopy Growth established a 100,000-square-foot indoor cultivation facility in Chonburi Province through a joint venture with Siam Wellness Group, investing approximately $85 million in infrastructure and genetics. Aurora Cannabis partnered with the Government Pharmaceutical Organization on clinical research examining cannabis treatments for chronic pain and epilepsy.

Both companies have paused expansion plans and written down asset values following the 2026 restrictions. Canopy Growth reported a $62 million impairment charge related to its Thai operations in its second quarter 2026 earnings statement. The companies maintain their cultivation licenses under the medical framework but face severely constrained market opportunities compared to initial projections.

Legal and Regulatory Framework

Current Legal Status Under 2026 Emergency Decree

Cannabis is classified as a controlled substance under Thailand's Narcotics Act as amended by the January 15, 2026 emergency decree. The decree reinstated cannabis as a Category 5 narcotic while creating exemptions for medical and research purposes. Unauthorized possession of cannabis flower or products exceeding 0.2 percent THC carries penalties of up to two years imprisonment and fines up to 200,000 baht ($5,600).

The decree establishes three tiers of legal cannabis products. Products containing less than 0.2 percent THC may be sold over-the-counter at licensed medical dispensaries without prescription, though purchasers must be 20 years or older and present government identification. Products containing 0.2 to 5 percent THC require physician prescriptions and may only be dispensed at licensed medical facilities. Products exceeding 5 percent THC are restricted to hospital settings for treatment of specific conditions including chemotherapy-related symptoms and severe epilepsy.

Medical Licensing Requirements

The Food and Drug Administration requires cannabis businesses to obtain medical facility licenses under regulations issued March 1, 2026. License applicants must demonstrate compliance with Good Manufacturing Practice standards, employ at least one licensed pharmacist or traditional medicine practitioner, maintain secure storage facilities, and implement inventory tracking systems. Application fees range from 50,000 baht ($1,400) for small dispensaries to 500,000 baht ($14,000) for cultivation facilities.

Licensed facilities must submit quarterly reports documenting all transactions, maintain patient prescription records for five years, and permit unannounced FDA inspections. Violations of licensing conditions result in immediate suspension and potential criminal prosecution for unauthorized distribution of controlled substances.

International Treaty Obligations

Thailand is a signatory to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The 2022 decriminalization created tensions with Thailand's treaty obligations, particularly provisions requiring parties to limit cannabis to medical and scientific purposes. The International Narcotics Control Board issued a statement in August 2022 expressing concern that Thailand's delisting of cannabis violated Single Convention requirements.

The 2026 medical-only framework represents Thailand's effort to align domestic policy with international treaty obligations. The Office of the Narcotics Control Board cited treaty compliance as a primary justification for the emergency decree, though critics note that the government could have pursued treaty reservation or withdrawal procedures rather than abrupt policy reversal.

Constitutional and Legal Challenges

Multiple legal challenges to the 2026 emergency decree remain pending before Thailand's Constitutional Court and Administrative Courts. The Thai Cannabis Trade Association filed a constitutional challenge in February 2026 arguing that the emergency decree violated property rights protections under Section 41 of the 2017 Constitution. The association contends that businesses made substantial investments in reliance on the government's 2022 delisting decision and that the abrupt reversal without compensation constitutes an unconstitutional taking.

A separate challenge filed by civil liberties organizations argues that the emergency decree exceeded the Prime Minister's constitutional authority by creating new criminal offenses without parliamentary approval. The Constitutional Court has not indicated when it will rule on these challenges, and the decree remains in effect pending judicial review.

Market and Business Implications

Economic Impact on Cannabis Industry

The medical-only restrictions have effectively destroyed Thailand's nascent cannabis industry, with estimated total losses exceeding 40 billion baht ($1.1 billion). The University of Thai Chamber of Commerce estimates that 10,200 of the 12,000 registered cannabis businesses will permanently close by the end of 2026. Inventory write-offs, lease termination costs, and equipment liquidation losses account for approximately 18 billion baht ($500 million) of the total impact.

Employment losses have been severe, with an estimated 38,000 direct job losses between January and August 2026. Ancillary industries including packaging suppliers, testing laboratories, and cannabis tourism operators have shed an additional 15,000 positions. The economic impact is concentrated in Bangkok and northern provinces where cannabis businesses were most prevalent.

Real Estate and Retail Sector Effects

Bangkok's retail real estate market faces significant disruption as cannabis dispensaries vacate prime commercial space. Landlords in tourist districts including Khao San Road and Sukhumvit report vacancy rates exceeding 30 percent as former cannabis tenants default on leases. Commercial real estate brokers estimate that approximately 180,000 square meters of retail space previously occupied by cannabis businesses has returned to the market, creating downward pressure on rents.

Some landlords have filed lawsuits against former cannabis tenants for unpaid rent and lease termination penalties. However, collection prospects are limited as most operators lack assets after inventory seizures and business closures. The retail disruption has created opportunities for other business categories, with restaurants, convenience stores, and traditional retail expanding into vacant spaces at reduced rents.

Medical Cannabis Market Projections

Industry analysts project Thailand's legal medical cannabis market will generate 2.5 to 3.5 billion baht ($70-100 million) in annual revenue under the current regulatory framework. This represents an 85 percent contraction from the estimated 18 billion baht ($500 million) in total cannabis sales during 2024. The medical market is constrained by prescription requirements, limited physician participation, and price points significantly higher than former retail dispensary pricing.

The Government Pharmaceutical Organization has expanded production of standardized medical cannabis extracts, targeting annual production capacity of 12,000 liters of cannabis oil by December 2026. However, patient uptake has been slower than projected, with only 45,000 active medical cannabis patients registered as of August 2026 compared to government projections of 150,000 patients by year-end.

Agricultural Sector Impact

Cannabis cultivation has contracted sharply following the 2026 restrictions, with planted acreage declining from an estimated 12,000 hectares in 2024 to approximately 1,800 hectares in 2026. Small farmers in northern provinces who had transitioned from rice and vegetable cultivation to cannabis face financial hardship as wholesale prices for legal medical-grade cannabis remain below production costs for most operators.

The Department of Agriculture estimates that 8,500 registered cannabis farmers have abandoned cultivation and returned to traditional crops. However, oversupply in rice and cassava markets has depressed prices for these commodities, leaving former cannabis farmers with limited profitable alternatives. Rural development advocates warn of increased poverty and migration to urban areas as agricultural income declines.

What Experts Say

Public health researchers at Mahidol University's Faculty of Medicine have documented both benefits and risks from Thailand's cannabis policy experiments. Dr. Prasert Auewarakul, a professor of virology and public health, noted in a July 2026 research presentation that medical cannabis access helped approximately 800,000 patients manage chronic conditions during the liberalization period. However, he also cited emergency department data showing increased adverse reactions and the absence of quality control standards as significant public health concerns.

The Thai Medical Association has consistently advocated for strict medical-only regulations with physician oversight. Association president Dr. Somsak Akksilp stated in a February 2026 press conference that unregulated cannabis sales created risks of youth access, impaired driving, and cannabis use disorder. The association supports the current medical framework but has called for increased government funding for physician education on cannabis therapeutics and expanded insurance coverage for medical cannabis treatments.

International drug policy experts view Thailand's reversal as a cautionary tale for emerging cannabis markets. Dr. Robin Room, a professor at Australia's La Trobe University and drug policy researcher, observed in an August 2026 interview that Thailand's experience demonstrates the importance of comprehensive regulatory frameworks before liberalization. He noted that the absence of age restrictions, potency limits, and quality control systems during the 2022-2026 period created conditions that undermined public support for reform.

Cannabis industry analysts have sharply criticized the abrupt policy reversal and lack of transition support for affected businesses. Bethany Gomez, managing director of the Brightfield Group, a cannabis market research firm, stated in a May 2026 industry report that Thailand's approach represents a worst-case scenario for policy instability. She noted that international cannabis companies will view Thailand as a high-risk jurisdiction for future investments regardless of potential policy changes.

Civil liberties advocates argue that the medical-only restrictions represent government overreach and violation of individual autonomy. Pornpen Khongkachonkiet, director of the Cross Cultural Foundation, a Thai human rights organization, has characterized the 2026 emergency decree as authoritarian policy-making that bypassed democratic processes. She contends that adult cannabis use should be regulated similarly to alcohol rather than criminalized.

What's Next

Near-Term Enforcement and Compliance (August-December 2026)

The Royal Thai Police and FDA will continue enforcement operations targeting unlicensed cannabis businesses through the remainder of 2026. The Office of the Narcotics Control Board has allocated 180 million baht ($5 million) for enforcement activities including raids, prosecutions, and public education campaigns. Authorities project that compliance rates will reach 95 percent by December 2026 as remaining unlicensed operators exhaust inventory or face criminal prosecution.

The FDA plans to approve an additional 400 to 600 medical cannabis licenses by year-end, focusing on hospital-based dispensaries and traditional medicine clinics in provincial capitals. However, licensing will remain concentrated in urban areas with limited access in rural regions where medical infrastructure is sparse.

Constitutional Court Decisions (Late 2026-Early 2027)

Thailand's Constitutional Court is expected to rule on legal challenges to the emergency decree between November 2026 and March 2027. Legal observers anticipate the court will uphold the government's authority to reclassify cannabis as a controlled substance, though it may require compensation for businesses that made investments in good-faith reliance on the 2022 delisting. A ruling requiring compensation could cost the government 15 to 25 billion baht ($420-700 million) and create fiscal pressures for the 2027 budget.

If the Constitutional Court invalidates the emergency decree on procedural grounds, Thailand would face a legal vacuum similar to the 2022-2026 period. However, most legal experts consider this outcome unlikely given the court's historical deference to executive authority on public health and security matters.

Legislative Prospects (2027-2028)

Comprehensive cannabis legislation remains stalled in Thailand's parliament with no clear path to passage before the next general election scheduled for May 2027. The Bhumjaithai Party has drafted legislation that would permit regulated adult-use sales with taxation, age restrictions, and potency limits. However, the bill lacks support from coalition partners including the Palang Pracharath Party and United Thai Nation Party, which favor maintaining medical-only access.

Election dynamics will determine future legislative prospects. If cannabis reform parties gain parliamentary seats in the 2027 election, comprehensive legalization legislation could advance in 2028. Conversely, gains by conservative parties would likely cement medical-only restrictions for the foreseeable future. Public opinion polling will be critical in shaping party positions during the campaign period.

Regional and International Implications

Thailand's policy reversal has strengthened opposition to cannabis reform across Southeast Asia. Singapore's Ministry of Home Affairs cited Thailand's experience in a July 2026 statement defending the city-state's capital punishment for drug trafficking. Malaysian and Indonesian officials have similarly referenced Thailand's reversal as evidence that cannabis liberalization creates public health and social problems.

The Association of Southeast Asian Nations is unlikely to pursue regional harmonization of cannabis policies given the stark divergence between Thailand's medical framework and the prohibitionist approaches maintained by most member states. This fragmentation complicates cross-border commerce and creates enforcement challenges as cannabis products flow through regional supply chains.

Medical Cannabis Program Development

The Ministry of Public Health plans to expand medical cannabis access through telemedicine consultations and community health centers during 2027. The Department of Medical Services is developing training programs to educate physicians on cannabis therapeutics, with a goal of certifying 5,000 doctors to prescribe medical cannabis by December 2027. The Government Pharmaceutical Organization is also developing standardized cannabis products in additional formulations including sublingual sprays, topical preparations, and suppositories.

Insurance coverage remains a critical barrier to medical cannabis access. The National Health Security Office, which administers Thailand's universal healthcare system, has not included cannabis products in the essential medicines list. Patients must pay out-of-pocket for medical cannabis, with monthly costs ranging from 3,000 to 8,000 baht ($85-225) depending on dosage and formulation. Advocacy organizations are lobbying for insurance coverage to improve access for low-income patients.

Further Reading

• Thailand Narcotics Act B.E. 2522 (1979) as amended by Emergency Decree B.E. 2569 (2026) - https://www.oncb.go.th
• Food and Drug Administration Medical Cannabis Licensing Regulations (March 1, 2026) - https://www.fda.moph.go.th
• Ministry of Public Health Cannabis Control Guidelines - https://www.moph.go.th
• Office of the Narcotics Control Board Annual Report 2025 - https://www.oncb.go.th/en
• University of Thai Chamber of Commerce Cannabis Industry Economic Impact Study (June 2026) - https://www.utcc.ac.th
• Thai Medical Association Position Statement on Cannabis Regulation (February 2026) - https://www.thaimed.or.th
• International Narcotics Control Board Annual Report 2026 - https://www.incb.org
• 1961 Single Convention on Narcotic Drugs - https://www.unodc.org
• Constitutional Court of Thailand Case Docket - https://www.constitutionalcourt.or.th
• Brightfield Group Thailand Cannabis Market Analysis (May 2026) - https://www.brightfieldgroup.com